Rachel Slyker
Associate
Rachel Slyker is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where her practice focuses on technology transactions and corporate law.
During law school, Rachel interned in the UCSF Industry Contracts Division. Prior to attending law school, she worked at Genentech, where she gained experience in bioprocessing.
Experience
Rachel Slyker is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where her practice focuses on technology transactions and corporate law.
During law school, Rachel interned in the UCSF Industry Contracts Division. Prior to attending law school, she worked at Genentech, where she gained experience in bioprocessing.
Education
- J.D., UC Berkeley School of Law, 2021
- M.S., Biotechnology, Johns Hopkins University, 2018
- B.S., Biochemistry and Cell Biology, University of California, San Diego, 2012
Cum Laude
Admissions
- State Bar of California
Credentials
Education
- J.D., UC Berkeley School of Law, 2021
- M.S., Biotechnology, Johns Hopkins University, 2018
- B.S., Biochemistry and Cell Biology, University of California, San Diego, 2012
Cum Laude
Admissions
- State Bar of California
Recent Illustrative Transactions
- Nosis Biosciences on its Research Collaboration and Option Agreement with Daiichi Sankyo
Matters
Recent Illustrative Transactions
- Nosis Biosciences on its Research Collaboration and Option Agreement with Daiichi Sankyo
Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Excellergy on $2 Billion Acquisition by Novartis
On March 27, 2026, Excellergy, a biotechnology company developing a novel class of allergy therapeutics, announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Nosis Bio on Strategic Collaboration and License Agreement with Johnson & Johnson
On March 24, 2026, Nosis Bio, a pioneer in AI-enabled cell-specific delivery for RNA medicines, announced an expansion of its strategic collaboration with Johnson & Johnson. Their initial collaboration has been expanded through an option exercise, and simultaneously, Nosis Bio and Johnson & Johnson have entered into a new strategic collaboration agreement focused on neurology. The collaborations will deploy Nosis’ Connexa™ platform, which combines a proprietary atlas of cell-specific internalizing receptor targets with physics-aware generative AI, to design delivery vehicles that can navigate complex cell types. Wilson Sonsini Goodrich & Rosati advised Nosis Bio on the transaction.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.